文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]AlF-NOTA-Asp2-PEG2-JR11的合成及临床前评价:一种用于生长抑素受体PET显像的新型拮抗剂放射性配体

Synthesis and preclinical evaluation of [18F]AlF-NOTA-Asp2-PEG2-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-11-13

本研究设计并合成新型SSTR拮抗剂[18F]AlF-NOTA-Asp2-PEG2-JR11,在AR42J/SSTR+及HCT116/SSTR-荷瘤鼠中比较其与[18F]AlF-NOTA-JR11和[68Ga]Ga-DOTA-TATE的临床前性能。结果显示该探针标记高效、体内稳定性好,60分钟肿瘤摄取与[18F]AlF-NOTA-JR11相当(9.26±0.49 vs 10.18±0.82%ID/g,p=0.147),两者均显著高于[68Ga]Ga-DOTA-TATE(6.79±0.29%ID/g,p=0.001),且该探针在多数正常器官中摄取最低、清除最快,肿瘤/背景比最高。

要点

  • 手动合成30分钟内完成,未校正放射化学产率39.56±3.25%(n>5),放射化学纯度>99%(n>5),2小时内放射化学纯度>95%。
  • 60分钟肿瘤摄取:[18F]AlF-NOTA-Asp2-PEG2-JR11 9.26±0.49 vs [18F]AlF-NOTA-JR11 10.18±0.82%ID/g(p=0.147),两者均显著高于[68Ga]Ga-DOTA-TATE 6.79±0.29%ID/g(p=0.001)。
  • [18F]AlF-NOTA-Asp2-PEG2-JR11在30分钟达肿瘤摄取峰值,在肾、骨、肝、肌肉等多数正常器官中摄取最低、清除最快,肿瘤/背景比随时间升高且为三者最高。

核心结论

  • [18F]AlF-NOTA-Asp2-PEG2-JR11合成高效,放射化学产率和放射化学纯度均高,体内稳定性好,肿瘤摄取高,肿瘤/背景比优于对照探针,是有前景的SSTR阳性肿瘤显像候选探针。

研究设计与样本

  • 临床前研究:一步法[18F]AlF螯合合成[18F]AlF-NOTA-Asp2-PEG2-JR11,在AR42J/SSTR+细胞中评估亲和力、内化和细胞摄取,在AR42J/SSTR+或HCT116/SSTR-荷瘤鼠中进行生物分布和PET/CT显像。

主要发现

  • 手动合成30分钟内完成,未校正放射化学产率39.56±3.25%(n>5),放射化学纯度>99%(n>5),2小时内放射化学纯度>95%。
  • 在AR42J细胞中,[18F]AlF-NOTA-Asp2-PEG2-JR11表现出高亲和力、特异性摄取和低内化,与[18F]AlF-NOTA-JR11相似。
  • 注射后60分钟肿瘤摄取:[18F]AlF-NOTA-Asp2-PEG2-JR11 9.26±0.49 vs [18F]AlF-NOTA-JR11 10.18±0.82%ID/g(p=0.147),两者均显著高于[68Ga]Ga-DOTA-TATE 6.79±0.29%ID/g(p=0.001)。
  • 共注射相应抑制剂后三种探针的肿瘤摄取均显著降低。
  • [18F]AlF-NOTA-Asp2-PEG2-JR11在注射后30分钟达肿瘤摄取峰值,在包括肾、骨、肝和肌肉的大多数正常器官中摄取最低、清除最快,使肿瘤/背景比随时间升高且为三种探针中最高。

关键数值与推荐

  • 未校正放射化学产率39.56±3.25%(n>5),放射化学纯度>99%(n>5),2小时内放射化学纯度>95%。
  • 60分钟肿瘤摄取:[18F]AlF-NOTA-Asp2-PEG2-JR11 9.26±0.49 vs [18F]AlF-NOTA-JR11 10.18±0.82%ID/g(p=0.147);[68Ga]Ga-DOTA-TATE 6.79±0.29%ID/g(p=0.001)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Somatostatin receptor (SSTR) antagonists have recently emerged as preferable radiotracers for SSTR-targeted imaging and therapy. This study aimed to design a novel SSTR antagonist, [18F]AlF-NOTA-Asp2-PEG2-JR11, and compare its preclinical performance with the previously reported antagonist, [18F]AlF-NOTA-JR11, and the agonist [68Ga]Ga-DOTA-TATE. METHODS: [18F]AlF-NOTA-Asp2-PEG2-JR11 was synthesized via a one-step radiolabeling process involving [18F]AlF chelation. The binding affinity, internalization, and cellular uptake were evaluated using AR42J/SSTR + cells. Biodistribution and PET/CT imaging were conducted in mice bearing xenografted AR42J/SSTR + or HCT116/SSTR- tumor xenografts. RESULTS: [18F]AlF-NOTA-Asp2-PEG2-JR11 was manually synthesized within 30 min with an uncorrected radiochemical yield of 39.56 ± 3.25% (n > 5) and radiochemical purity (RCP) exceeding 99% (n > 5). [18F]AlF-NOTA-Asp2-PEG2-JR11 demonstrated excellent in vivo stability over 2 h (RCP > 95%). Among AR42J cells, [18F]AlF-NOTA-Asp2-PEG2-JR11 exhibited high affinity, specific uptake, and low internalization, similar to [18F]AlF-NOTA-JR11. Biodistribution and micro-PET/CT imaging studies revealed comparable tumor uptake between [18F]AlF-NOTA-Asp2-PEG2-JR11 and [18F]AlF-NOTA-JR11 (9.26 ± 0.49 vs. 10.18 ± 0.82%ID/g, p = 0.147) at 60 min post-injection (p.i), both were significantly higher than [68Ga]Ga-DOTA-TATE (6.79 ± 0.29%ID/g, p = 0.001). Co-injecting the corresponding inhibitor significantly reduced the tumor uptake of all three tracers. Notably, [18F]AlF-NOTA-Asp2-PEG2-JR11 reached peak tumor uptake at 30 min p.i. and exhibited the lowest uptake and fastest clearance in most normal organs, including the kidney, bone, liver, and muscle, resulting in the highest and increasing tumor-to-background ratios (TBR) over time among the three tracers. CONCLUSION: The synthesis of [18F]AlF-NOTA-Asp2-PEG2-JR11 is efficient, with high radiochemical yield and RCP. [18F]AlF-NOTA-Asp2-PEG2-JR11 exhibits excellent in vivo stability, high tumor uptake, and superior TBR, making it a promising potential tracer for imaging SSTR-positive tumors.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liang H, Chen Z, Mo C, et al. Synthesis and preclinical evaluation of [18F]AlF-NOTA-Asp2-PEG2-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor. Eur J Nucl Med Mol Imaging. 2024. PMID: 39532749. doi:10.1007/s00259-024-06978-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。